Rastislav Balheda

机构：Institut Gustave Roussy · ORCID：0009-0003-8257-6053

发表论文 13 篇 · 总被引 190 次 · h-index 2

代表论文

Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials (2013 · Clinical Cancer Research · 被引 180)
Rhinitis and epistaxis in patients treated by anti-angiogenic therapy (2008 · Investigational New Drugs · 被引 10)
Gustave Roussy Immune (GRIm) score validation in patients treated with Bispecific CD3 T-cell engagers in phase I clinical trials. (2026 · Cancer Research Communications)
Supplementary Table 1 from Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials (2023)
Supplementary Table 3 from Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials (2023)
Supplementary Table 2 from Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials (2023)